393 related articles for article (PubMed ID: 19304319)
1. The augmentation of intracellular delivery of peptide therapeutics by artificial protein transduction domains.
Yoshikawa T; Sugita T; Mukai Y; Abe Y; Nakagawa S; Kamada H; Tsunoda S; Tsutsumi Y
Biomaterials; 2009 Jul; 30(19):3318-23. PubMed ID: 19304319
[TBL] [Abstract][Full Text] [Related]
2. Cationic TAT peptide transduction domain enters cells by macropinocytosis.
Kaplan IM; Wadia JS; Dowdy SF
J Control Release; 2005 Jan; 102(1):247-53. PubMed ID: 15653149
[TBL] [Abstract][Full Text] [Related]
3. Intracellular protein delivery activity of peptides derived from insulin-like growth factor binding proteins 3 and 5.
Goda N; Tenno T; Inomata K; Shirakawa M; Tanaka T; Hiroaki H
Exp Cell Res; 2008 Aug; 314(13):2352-61. PubMed ID: 18602100
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo.
Mi Z; Mai J; Lu X; Robbins PD
Mol Ther; 2000 Oct; 2(4):339-47. PubMed ID: 11020349
[TBL] [Abstract][Full Text] [Related]
5. A peptide carrier for the delivery of biologically active proteins into mammalian cells.
Morris MC; Depollier J; Mery J; Heitz F; Divita G
Nat Biotechnol; 2001 Dec; 19(12):1173-6. PubMed ID: 11731788
[TBL] [Abstract][Full Text] [Related]
6. Organelle-targeted delivery of biological macromolecules using the protein transduction domain: potential applications for Peptide aptamer delivery into the nucleus.
Yoshikawa T; Sugita T; Mukai Y; Yamanada N; Nagano K; Nabeshi H; Yoshioka Y; Nakagawa S; Abe Y; Kamada H; Tsunoda S; Tsutsumi Y
J Mol Biol; 2008 Jul; 380(5):777-82. PubMed ID: 18571668
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo.
Kim D; Jeon C; Kim JH; Kim MS; Yoon CH; Choi IS; Kim SH; Bae YS
Exp Cell Res; 2006 May; 312(8):1277-88. PubMed ID: 16466653
[TBL] [Abstract][Full Text] [Related]
8. Intracellular transduction using cell-penetrating peptides.
Sawant R; Torchilin V
Mol Biosyst; 2010 Apr; 6(4):628-40. PubMed ID: 20237640
[TBL] [Abstract][Full Text] [Related]
9. Protein transduction: identification, characterization and optimization.
Tilstra J; Rehman KK; Hennon T; Plevy SE; Clemens P; Robbins PD
Biochem Soc Trans; 2007 Aug; 35(Pt 4):811-5. PubMed ID: 17635154
[TBL] [Abstract][Full Text] [Related]
10. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer.
Wadia JS; Dowdy SF
Adv Drug Deliv Rev; 2005 Feb; 57(4):579-96. PubMed ID: 15722165
[TBL] [Abstract][Full Text] [Related]
11. Cellular uptake and lysosomal delivery of galactocerebrosidase tagged with the HIV Tat protein transduction domain.
Zhang XY; Dinh A; Cronin J; Li SC; Reiser J
J Neurochem; 2008 Feb; 104(4):1055-64. PubMed ID: 17986221
[TBL] [Abstract][Full Text] [Related]
12. Cationic and tissue-specific protein transduction domains identification, characterization, and therapeutic application.
Zahid M; Lu X; Mi Z; Robbins PD
Adv Genet; 2010; 69():83-95. PubMed ID: 20807603
[TBL] [Abstract][Full Text] [Related]
13. [Reconstruction of an intracellular transduction system based on HIV-1 TAT protein transduction domain].
Guo AH; Liu ZF; Sun XG; Li HY; Deng P; Jiang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2006 May; 26(5):545-8. PubMed ID: 16762844
[TBL] [Abstract][Full Text] [Related]
14. Novel RasGRF1-derived Tat-fused peptides inhibiting Ras-dependent proliferation and migration in mouse and human cancer cells.
Sacco E; Metalli D; Spinelli M; Manzoni R; Samalikova M; Grandori R; Morrione A; Traversa S; Alberghina L; Vanoni M
Biotechnol Adv; 2012; 30(1):233-43. PubMed ID: 21620943
[TBL] [Abstract][Full Text] [Related]
15. The kinetics and tissue distribution of protein transduction in mice.
Cai SR; Xu G; Becker-Hapak M; Ma M; Dowdy SF; McLeod HL
Eur J Pharm Sci; 2006 Mar; 27(4):311-9. PubMed ID: 16376528
[TBL] [Abstract][Full Text] [Related]
16. Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide.
Sugita T; Yoshikawa T; Mukai Y; Yamanada N; Imai S; Nagano K; Yoshida Y; Shibata H; Yoshioka Y; Nakagawa S; Kamada H; Tsunoda S; Tsutsumi Y
Biochem Biophys Res Commun; 2007 Nov; 363(4):1027-32. PubMed ID: 17923117
[TBL] [Abstract][Full Text] [Related]
17. Engineering, cloning, and functional characterization of recombinant LIM mineralization protein-1 containing an N-terminal HIV-derived membrane transduction domain.
Sangadala S; Okada M; Liu Y; Viggeswarapu M; Titus L; Boden SD
Protein Expr Purif; 2009 Jun; 65(2):165-73. PubMed ID: 19284982
[TBL] [Abstract][Full Text] [Related]
18. Transport molecules using reverse sequence HIV-Tat polypeptides: not just any old Tat? (WO200808225).
Howl J; Jones S
Expert Opin Ther Pat; 2009 Sep; 19(9):1329-33. PubMed ID: 19555160
[TBL] [Abstract][Full Text] [Related]
19. Intracellular cargo delivery using tat peptide and derivatives.
Zhao M; Weissleder R
Med Res Rev; 2004 Jan; 24(1):1-12. PubMed ID: 14595670
[TBL] [Abstract][Full Text] [Related]
20. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides.
Snyder EL; Saenz CC; Denicourt C; Meade BR; Cui XS; Kaplan IM; Dowdy SF
Cancer Res; 2005 Dec; 65(23):10646-50. PubMed ID: 16322205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
